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Select: Gut MicrobesOur intestines host trillions of bacteria, most of which are beneficial to our health most of the time. Occasionally,
however, a change in conditions, or the entry of a pathogenic strain, leads to disease. Recent papers shed new light
onto the complex interactions that determine intestinal health and disease.Intraepithelial lipopolysaccharide
(red) in a 6-day-old mouse gut
promotes epithelial tolerance.
Image courtesy of M. Hornef.Preparing the Gut for Bacterial Encounter
Intestinal cells first come into contact with bacteria after birth, as they transition from
the sterile uterine environment to the outside microbe-filled world. Given that encoun-
ters with bacteria normally trigger immune activation and inflammation, which may
cause tissue damage, neonatal intestinal epithelial cells are programmed to undergo
a period of tolerance, in which bacteria do not elicit an immune response. Chassin
et al. (2010) now show in mouse that during tolerance the microRNA miR-146a
suppresses the inflammatory pathway mediated by Toll-like receptors by repressing
the translation of the interleukin 1 receptor associated kinase 1 (IRAK1). Things, how-
ever, are not as simple as they seem. In a surprising twist, the authors find that Toll-like
receptor 4 (TLR4) signaling in the neonate epithelium is required for the downregulation
of IRAK1. Furthermore, both TLR4 and IRAK1 are required for maintaining elevated
miR-146a levels, and both are also required for expression of genes that regulate
cell survival, differentiation, andmetabolism and hence promote cellular homeostasis.
In otherwords, the immunepathway is not simply turnedoff at birth but is rather actively
modulated to accomplish tolerance and to allow intestinal cells to express the set
of genes necessary for their maturation. Interestingly, the authors find that IRAK1
expression reappears at weaning (21 days after birth in mice), when mice begin eatingsolid food—the point atwhichmicemay encounter pathogenic bacteria and need tomount an immune response. At this
time epithelial proliferation increases, ending the continuous TLR4/IRAK1 signaling that maintains tolerance and
lowering miR-146a expression. The ultimate triggers that initiate and end tolerance remain unknown, however, and it
would be particularly interesting to study the regulation of the corresponding pathway in humans. Despite significant
differences in the maturity of the neonate gut between mice and men, both have to cope with the sudden exposure
to microbial stimuli after birth and to establish a life-long, stable host-microbe homeostasis.
C. Chassin et al. (2010). Cell Host Microbe 8, 1–11.The epithelium (green) of the zebra-
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K. Guillemin.Microbes Give Epithelial Proliferation a Boost
Rapid turnover of epithelial cells is a hallmark of healthy intestines. The rate of prolif-
eration is regulated by both Wnt signaling and microbes, at least in adult tissue. A
study from the Guillemin lab (Cheesman et al., 2010) now investigates the roles of
microbes and Wnt signaling during development in the intestines of zebrafish larvae.
The larval period corresponds to the time zebrafish first encounter microbes, analo-
gous to the neonatal period in humans and mice, and is the time when the epithelial
proliferation rate is first established in the intestines. Cheesman et al. (2010) find
that microbes in the larval gut and Wnt signaling promote epithelial proliferation, as
they do in adults. They then ask whether microbes use the Wnt pathway to promote
proliferation and find that the answer is complex. They provide evidence that one
particular resident bacterium, Aeromonas veronii, secretes a proliferation signal that
acts on intestinal cells to promote the accumulation of b-catenin, a key component
of the Wnt signaling pathway. A mutation in TCF4, a transcription factor downstream
of Wnt signaling, partially blocks the effect of A. veronii on cell proliferation. These
results suggest that resident microbes promote proliferation in part through effects on the Wnt pathway. However,
the authors also show that axin, an upstream regulator of the Wnt pathway, does not affect the response to microbes,
and that microbes act through the Myd88 protein, an adaptor downstream of Toll-like receptors (TLRs). Thus, it seems
that the microbial pathway for regulating proliferation intersects the Wnt pathway but also acts independently, through
a mechanism that will need to be explored in future studies.
S. Cheesman et al. (2010). Proc. Natl. Acad. Sci. USA. Published online October 4, 2010. 10.1073/pnas.1000072107.Cell 143, October 29, 2010 ª2010 Elsevier Inc. 331
S. Typhimurium. Image by RockyMountain Labora-
tories, NIAID, NIH.Thriving in Inflammation’s Wake
Winter et al. (2010) report an ingenious strategy used by the enteric
pathogen Salmonella enterica serotype Typhimurium to create a growth
advantage for itself in the gut. In so doing, the authors tie together two
previously unrelated observations: (1) that S. Typhimurium causes acute
intestinal inflammation, which allows the bacterium to outcompete other
microbes in the gut, and (2) that S. Typhimurium can use tetrathionate as
an electron acceptor for respiration leading to enhanced growth, at
least in vitro. Winter et al. now show that inflammation caused by the
pathogen leads to production of tetrathionate in the mouse intestine.
The authors show that a compound produced in the cecum, thiosulfate
(S2O3
2), can be converted to tetrathionate by reactive oxygen species,
which are produced by neutrophils during inflammation. Salmonella
strains lacking ttrA, a gene required for tetrathionate-dependent
respiration, do not grow as well as wild-type bacteria both in vitro and
in vivo, and in vivo they cannot outcompete other microbes in the gut.
The paper thus suggests that Salmonella has a good reason for inducing
inflammation in the intestine: byproducts of inflammation, including
oxygen radicals and tetrathionate, allow it to thrive. The authors mention
that another enteric pathogen, Yersinia enterocolitica, also harbors thegene cluster that confers tetrathionate respiration ability, and future work will reveal whether other pathogenic bacteria
use similar mechanisms for competing with host microbes. These results also raise the possibility of targeting the
tetrathionate respiration pathway to specifically inhibit the growth of pathogens and not resident bacteria.
S. Winter et al. (2010). Nature 467, 426–429.C. difficile bacteria. Image courtesy of S. Baban.Bacterial Toxins’ Multiple Choice: A or B
Clostridium difficile infections cause life-threatening diarrhea and
inflammation, occurring most frequently when antibiotic treatment
eliminates other bacterial strains in the intestine. C. difficile produces
two toxins, toxin A and toxin B, that both target Rho GTPases, leading
to cytoskeletal disruption. Previous reports came to conflicting conclu-
sions regarding the relative importance of each toxin to the virulence
ofC. difficile. Some studies suggest that toxin A is sufficient for bacterial
virulence, and that toxin B alone cannot cause virulence, whereas
another study suggests the opposite, that toxin B was virulent on its
own, but not toxin A. Kuehne et al. (2010) re-examine this issue by
generating mutant strains of C. difficile lacking toxin A, toxin B, or
both. They show that strains harboring just one toxin, either A or B,
are virulent both in cultured cells and in a hamster model for the disease. Only when both toxins are knocked out
(in a double-mutant strain, the first double mutant produced in C. difficile) does the bacteria become avirulent. The
authors conclude that both toxins contribute to the disease and suggest that both need to be taken into account in
the design of treatments for C. difficile infections. Given that both toxins are glucosyltransferases targeting the
same GTPases, the results do raise the question of why the bacteria need two toxins, and what, if any, advantage
having both toxins confers.
S. Kuehne et al. (2010). Nature 467, 711–714.
Ilil CarmiCell 143, October 29, 2010 ª2010 Elsevier Inc. 333
